Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2021.12576

OL-0-0-12576

Review

Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs

Dong

Mei

1 * Wang

Rujian

2 * Sun

Ping

2 Zhang

Dongxia

1 Zhang

Zhenzhen

1 Zhang

Jing

1 Tse

Gary

3 Zhong

Lin

1Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China 2Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China 3Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China

Correspondence to: Dr Lin Zhong, Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, 20 Yuhuangding East Road, Yantai, Shandong 264000, P.R. China, E-mail: yizun1971@126.com Dr Gary Tse, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin 300211, P.R. China, E-mail: gary.tse@doctors.org.uk *

Contributed equally

04 2021

23 02 2021

21 4

315

23082020 13012021

2021

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Hypertension is a common comorbidity in patients receiving antiangiogenic therapy. Prior studies have reported worsening or new-onset hypertension as an adverse event of antiangiogenetic therapy, which can be managed by dose reduction or discontinuation of the culprit medication. By contrast, other studies have found that the occurrence of hypertension is a potential biomarker associated with greater efficacy of antiangiogenic therapy and predicts improved survival. At present, there is no consensus on the effects of hypertension in patients treated with antiangiogenic drugs. The present study reviewed the relationship between antiangiogenic drugs and hypertension in different types of cancer. It was demonstrated that the use of antiangiogenic drugs was associated with an increased risk of hypertension in most types of solid cancers. There was no significant difference in the incidence of hypertension between monoclonal antibody and small-molecule tyrosine kinase inhibitor treatments. Hypertension was more likely to occur in patients younger than 75 years old, female, and those with no history of bevacizumab use. Discontinuation or death caused by hypertension was rare, although previous studies have reported that hypertension was a risk factor for acute and chronic cardiovascular diseases and ischemic stroke. Of note, the early development of hypertension may serve as a potential biomarker associated with greater efficacy of antiangiogenic therapy.

anti-angiogenic drugs hypertension cancers biomarker clinical significance

1. Introduction

Angiogenesis is a crucial enabling process for tumor growth and metastasis (1). The vascular endothelial growth factor (VEGF) signaling pathway serves a key role in the angiogenesis of solid tumors. The VEGF signaling system is complex and consists of five related ligands: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PLGF). They bind with different specificities to three receptor tyrosine kinases: VEGFR1, VEGFR2 and VEGFR3 (2). VEGF pathway-targeting agents include monoclonal antibodies, such as bevacizumab and ramucirumab, and small-molecule tyrosine kinase inhibitors (TKIs), such as sunitinib, sorafenib, apatinib and regorafenib. Monoclonal antibodies block the binding of VEGF to VEGFR and prevent activation of intracellular signal transduction (3). Small-molecule TKIs act on the intracellular domain of the endothelial receptor, where they inhibit the initial phosphorylation step following the ligand-receptor interaction (4). These drugs can slow down the growth of tumors effectively and improve the progression-free survival (PFS) and overall survival (OS) of patients with cancer (2).

However, a previous study has reported that antiangiogenic therapy increased arterial blood pressure (BP), raised the risk of new-onset hypertension, or worsened existing hypertension (5). The mechanism underlying the antiangiogenic drug-induced hypertension remains controversial. The current hypotheses include decreased nitric oxide (NO) (6), increased endothelin-1 (7), capillary rarefaction (8) and activation of the renin-angiotensin-aldosterone system (RAAS) (9) (Fig. 1). According to the National Cancer Institute's common terminology criteria for adverse events (NCI CTCAE), version 5.0 (10), hypertension for adults can be classed into five categories depending on its severity (Table I). Subsequently, the presence of hypertension can lead to a reduction or interruption of antiangiogenic therapy (11).

Considering the complex relationship between antihypertensive drugs and cancer, the cancer type, the pre-existing comorbidities and the presence of contraindications should be considered when selecting antihypertensive drugs for patients with cancer (12). Currently, angiotensin-converting enzyme inhibitors (ACEIs) are the preferred first-line option in treatment of hypertension induced by anti-VEGF chemotherapy, given its improved outcome in several types of cancer (13). On the other hand, several retrospective studies (14,15) have found that the appearance of hypertension during antiangiogenic therapy might be associated with improved survival. Thus, it remains unclear whether hypertension should be considered as an adverse reaction or as a positive prognostic marker in patients with various types of cancer. The present review aimed to explore the relationship between hypertension and antiangiogenic therapy in different types of tumors.

2. Relationship between antiangiogenic therapy and hypertension in renal cell cancer

In total, nine studies have reported the association between hypertension and antiangiogenic drugs, including sunitinib, bevacizumab, sorafenib, axitinib and pazopanib, in renal cell carcinoma (RCC). Of these nice studies, seven were prospective studies (16–22) and two were retrospective studies (23,24), involving a total of 6,083 patients (Table II).

Hypertension as an adverse event of antiangiogenic therapy

Four phase III, randomized, double-blind, placebo-controlled trials (16–18,20) and a phase II, randomized, double-blind trial (19) demonstrated that antiangiogenic drugs increased the risk of hypertension in patients with RCC. Increased BP due to axitinib gradually dropped to baseline after the end of treatment (19). The incidence of hypertension in the TKI treatment group (33.2%) was higher compared with the group treated with monoclonal antibodies (27.4%). It is worth noting that the axitinib group had the highest incidence of severe hypertension [≥grade (G) 3 hypertension]. Compared with the aforementioned studies, hypertension was more frequently observed in the Donskov et al study (24), which could be attributed to the different definition of hypertension used. Furthermore, the risk of hypertension may be dose-dependent (19), however, no association with nephrectomy was observed (16). Thus, further research is needed to provide more evidence for the association between antiangiogenic treatment and the risk of hypertension in patients with RCC.

<sec> <title>Hypertension as a biomarker of antiangiogenic therapy

Two studies (22,23) found that significant hypertension (≥G2) may be a potential biomarker associated with greater efficacy. In addition, another study using real-world data from Japan demonstrated that patients with hypertension have a higher 24-week OS and PFS rate (21). Donskov et al (24) found that on-treatment hypertension is an independent biomarker of sunitinib efficacy. These studies did not report the median time of hypertension-onset. However, Goldstein et al (25) found that hypertension caused by pazopanib or sunitinib was not a biomarker in the treatment of metastatic RCC.

3. Relationship between antiangiogenic therapy and hypertension in gastric cancer and gastroesophageal junction cancers

As an adjuvant treatment of gastric cancer, antiangiogenic drugs significantly prolong the survival of patients with advanced or metastatic gastric cancer (GC) in addition to gastroesophageal junction carcinoma (GEJ), and hypertension is a common adverse reaction that cannot be ignored. Five studies have reported the association between hypertension and antiangiogenic drugs, including apatinib and ramucirumab, of which, four were prospective studies (26–29) and one was a retrospective study (15). In total, 1,700 patients were included (Table III).

<sec> <title>Hypertension as an adverse event of antiangiogenic therapy

Two double-blind, randomized, placebo-controlled, phase III trials for ramucirumab (27,28) and the phase II and III studies for apatinib (26,29) showed that ramucirumab and apatinib increased the risk of ≥G3 hypertension in patients with GC or GEJ carcinoma. The incidence of hypertension in the TKI treatment group (36.80%) was higher compared with the group treated with monoclonal antibodies (22.78%). However, the incidence of severe hypertension in the monoclonal antibody treatment group (11.37%) was higher compared with the TKI-treated group (6.32%). Of note, the incidence of severe hypertension was higher in the dose of 425 mg twice daily compared with the dose of 850 mg once-daily regimen (26), but this comparison lacked statistical significance.

Hypertension as a biomarker of effective antiangiogenic therapy

A retrospective cohort study of 269 patients demonstrated that the presence of hypertension within the first four weeks of antiangiogenic therapy was associated with prolonged median overall survival (15), suggesting that hypertension is an early prognostic marker. However, further studies are required to support this conclusion.

4. Relationship between antiangiogenic therapy and hypertension in lung cancer

Bevacizumab is the most widely used antiangiogenic drug for lung cancer treatment. Twelve studies have reported the association between hypertension and approved antiangiogenic drugs, including fruquintinib, crediranib anlotinib and bevacizumab. There are seven prospective studies (30–36), two retrospective studies (14,37) and three meta-analyses (38–40). A total of 1,1291 patients were included (Table IV).

<sec> <title>Hypertension as an adverse event of antiangiogenic therapy

Bevacizumab increased the risk of severe hypertension in the high-dose group (15 mg/kg) (32,39) and amongst female patients (41). There was no significant difference between different races (30), pathological types (38) and age (42). Discontinuation of medication due to hypertension was extremely rare (30,39). Based on these data, it was found in the present study that the incidence of hypertension in the TKI treatment group (59.72%) was higher compared with the group treated with the monoclonal antibodies (28.61%). The incidence of hypertension was the highest in the anlotinib group (67.3%). A total of 13.6% patients developed severe hypertension during therapy. Notably, 23% of patients developed severe hypertension when receiving bevacizumab plus erlotinib (34).

Hypertension as a biomarker of antiangiogenic therapy

Two studies of bevacizumab (14,37) and one study of cediranib (36) suggested that the early development of hypertension was associated with clinical benefit.

5. Relationship between antiangiogenic therapy and hypertension in colorectal cancer

Antiangiogenic therapy improved the overall survival of patients with colorectal cancer, but its benefit is offset partially by adverse events, such as hypertension. Thirteen studies have reported significant associations between hypertension and antiangiogenic drugs, including bevacizumab, ramucirumab and fruquintinib. There are six prospective studies (43–48), three retrospective studies (14,49,50), three meta-analyses (51–53) and one cohort study (54), including a total of 22,639 patients (Table V).

Hypertension as an adverse event of antiangiogenic therapy

A meta-analysis of 10,180 participants treated with bevacizumab (51), two randomized controlled studies for regorafenib (47) and a phase III controlled trial for ramucirumab (55) showed that these drugs increased the incidence of severe hypertension in patients with colorectal cancer. Hypertension caused by antiangiogenic drugs was associated with age (43,56,57) and regimen (58), but no association was observed with VEGF-D levels (55), race (59), cancer stage (45) or treatment line (47,48). Based on the aforementioned studies, the incidence of severe hypertension in the monoclonal antibodies group (13.11%) was higher than the TKI group (9.14%). Notably, bevacizumab was less likely to induce severe hypertension in elderly patients (age, ≥75 years) (43,56,57).

Hypertension as a biomarker of antiangiogenic therapy

Three retrospective studies (14,49,50) and a cohort study (54) of bevacizumab showed that early developing hypertension may be a predictive marker for the efficacy of bevacizumab.

Examples of trials that did not increase the risk of hypertension

Other studies have reported that bevacizumab did not significantly increase the risk of severe hypertension in patients receiving the drug (60,61) and patients who were aged ≥70 (57). However, the former conclusion may have selection bias, because amongst the patients who have previously received bevacizumab treatment, only patients who have not developed severe hypertension receive bevacizumab treatment again.

6. Relationship between antiangiogenic therapy and hypertension in hepatocellular carcinoma

Antiangiogenic drugs have an important role in the treatment of hepatocellular carcinoma (62). Five studies have reported the association between hypertension and antiangiogenic drugs, including cabozantinib, regorafenib, sorafenib and ramucirumab, in hepatocellular carcinoma. There are four prospective studies (63–66) and one retrospective study (67). A total of 2,272 patients were included (Table VI).

<sec> <title>Hypertension as an adverse event of antiangiogenic therapy

Four phase III, randomized, double-blind, placebo-controlled trials of antiangiogenic drugs, including cabozantinib, regorafenib and ramucirumab, reported an increasing risk of severe hypertension in the drug-treated group, with an incidence of 13–16% (63–66). Based on the given data, it was found in the present study that the incidence of severe hypertension in the TKI-treated group (14.51%) was moderately greater compared with the monoclonal antibodies-treated group (13.66%).

Hypertension as a biomarker of antiangiogenic therapy

One retrospective study of 38 patients suggested that hypertension within two weeks of therapy initiation may be a positive predictor of the anticancer efficacy of sorafenib in patients with hepatocellular carcinoma (67).

Examples of trials that did not increase the risk of hypertension

Three multicenter, phase III, double-blind, placebo-controlled trials showed that sorafenib did not significantly increase the risk of severe hypertension in patients with advanced hepatocellular carcinoma (68–70). This may be a unique manifestation of sorafenib in hepatocellular carcinoma.

7. Relationship between antiangiogenic therapy and hypertension in breast cancer

Antiangiogenic agents have been used extensively for the treatment of breast cancer, but high rates of treatment-induced hypertension have been reported (71). Six studies have reported the association between hypertension and antiangiogenic drugs including, bevacizumab and axitinib, in breast cancer. There are four prospective studies (72–75), one retrospective study (76) and one meta-analysis (77), with a total of 7,414 patients included (Table VII).

<sec> <title>Hypertension as an adverse event of antiangiogenic therapy

A meta-analysis of five clinical trials reported that bevacizumab increased the risk of severe hypertension (77). Severe hypertension was more frequent in the high-dose group (73) and in some specific genotypes (76). In specific, Schneider et al (76) demonstrated that those with VEGF-1498TT and VEGF-634CC genotypes were largely protected from severe hypertension. There was no clear correlation between severe hypertension and baseline blood pressure (78). Based on the given data, it was found in the present study that the incidence of severe hypertension in the TKI-treated group (17.5%) was higher compared with the monoclonal antibodies-treated group (6.6%).

Hypertension as a biomarker of antiangiogenic therapy

Biomarker analysis of the Eastern Cooperative Oncology Group clinical trial E2100 demonstrated that patients with severe hypertension had a superior median overall survival, and that the VEGF-2578 AA genotype was associated with improved outcome (76). Another study of apatinib showed that the predictive effect of hypertension was not related to the grade of hypertension (75).

8. Discussion

The present brief review examined the association between hypertension and antiangiogenic therapy in different types of cancer. There are several key findings reported in the present review. First, the use of antiangiogenic drugs was associated with an increased risk of hypertension in most types of solid cancer. Based on the analyzed data, the incidence of hypertension (33.39%) was the highest in lung cancer. In addition, the incidence of severe hypertension was the highest in hepatocellular carcinoma (13.48%) and the lowest in breast cancer (7.1%). Second, there was no significant difference in the incidence of hypertension between monoclonal antibodies and small molecule TKI treatments. Of note, the use of several novel TKIs has been associated with a higher incidence of severe hypertension, such as axitinib in renal cell cancer (18%) (19), fruquintinib in colorectal cancer (29.8%) (48), apatinib in breast cancer (17.5%) (75), and combination of bevacizumab with erlotinib in lung cancer (23%) (34). However, this effect was not observed in the combined antiangiogenic immunotherapy arm (79). In addition, hypertension as an adverse event was more common in patients receiving high doses (41), however, the effect of frequency of administration on the occurrence of hypertension remains unclear. Third, hypertension was more likely to occur in patients younger than 75 years old (43,56,57), those who have not previously used bevacizumab (60,61), and female patients (41). Fourth, the effect of baseline blood pressure levels on the development of hypertension is controversial. Pivot et al (78) reported that there was no clear correlation between baseline hypertension and its development during study treatment. By contrast, Yang et al (80) found that a history of hypertension was an independent risk factor for predicting hypertension during the treatment period. Fifth, discontinuation or death caused by hypertension was rare. Nevertheless, hypertension was a risk factor for acute and chronic cardiovascular diseases and ischemic stroke, with the grade of hypertension associated with mortality (77,81). Finally, early development of significant hypertension may be a biomarker associated with greater efficacy of antiangiogenic therapy and improved survival (14,49,50).

Large doses of antiangiogenic agents are generally associated with greater inhibitory effects on VEGF. We speculate that higher sensitivity to angiogenesis inhibitors may be an explanation, due to different levels of VEGF expression. Patients with RCC have increased levels of VEGF and VEGFR expression (82), which is accompanied by higher rates of hypertension development, compared with hepatocellular carcinoma patients treated with sorafenib (83). Frey et al (84) have shown that bevacizumab-induced hypertension is related to genetic variation in WNK lysine deficient protein kinase 1, kallikrein B1 and G protein-coupled receptor kinase 4. The performance of sunitinib in patients with non-small cell lung cancer (85), bevacizumab in Chinese patients with locally progressed GC (86), as well as sorafenib (87) and sunitinib (88) in patients with breast cancer, confirms our hypothesis: These drugs did not increase the risk of serious hypertension, but at the same time, they did not improve survival.

As an adverse event, hypertension caused by antiangiogenic drugs should be monitored regularly by physicians. There is a role for home or ambulatory blood pressure monitoring, which can increase the sensitivity of diagnosing hypertension (89). Nevertheless, blood pressure monitoring in the clinic is recommended for the first cycle of therapy (90). When blood pressure remains <140/90 mmHg, lifestyle intervention is recommended, which includes lower salt intake, reduced alcohol consumption, normalization of the body mass index, no cigarette smoking and increased physical activity (91). Antihypertensive therapy should be initiated when blood pressure is >140/90 mmHg or 20 mmHg greater than the baseline blood pressure (90). The association between antihypertensive drugs and cancer is a matter of large debate in the last several years. At present, renin inhibitors, including ACEIs and angiotensin receptor blockers, are the first-line agents preferred for antiangiogenetic therapy, since they can improve remodeling by reducing left ventricular afterload and by direct inhibition of angiotensin II type 1 receptor-mediated hypertrophy and fibrosis (13). After the end of antiangiogenic drug treatment, blood pressure should be regularly monitored, and antihypertensive treatment should be discontinued if it normalizes.

On the other hand, the presence of hypertension has been reported as a positive prognostic biomarker of improved survival in patients receiving antiangiogenic therapy. However, the underlying mechanisms, the timing and value of blood pressure that best predicts survival needs to be elucidated. Previous studies have shown that significant hypertension [≥G2 (22,23) or ≥G3 (76)] and early occurrence of hypertension [in the first two (67), four (15) or six weeks of treatment initiation (21)] may be associated with improved survival. However, it is unclear whether patients who do not develop significant hypertension in the early stage need alterations in the medication regimen (15).

9. Conclusion

In conclusion, the use of antiangiogenic drugs is associated with an increased risk of hypertension in most types of solid cancer. Early development of significant hypertension may be a potential biomarker of improved survival. Prospective studies are needed to support these findings.

Acknowledgements

The authors would like to thank Dr Sharen Lee (Cardiovascular Analytics Group, Laboratory of Cardiovascular Physiology, Hong Kong) for his contribution to the revision of the manuscript and data interpretation.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

GT, PS and LZ designed and arranged the manuscript. MD and RW wrote the article. DZ, ZZ and JZ found and analyzed the references in Medline, and participated in writing the article. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Hanahan

Weinberg

Hallmarks of cancer: The next generation

Cell1446466742011

10.1016/j.cell.2011.02.013

21376230

Vasudev

Reynolds

Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions

Angiogenesis174714942014

10.1007/s10456-014-9426-5

24482243

Brinda

Viganego

Dolan

Fradley

Anti-VEGF-induced hypertension: A review of pathophysiology and treatment options

Curr Treat Options Cardiovasc Med18332016

10.1007/s11936-016-0452-z

26932588

Eskens

Verweij

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review

Eur J Cancer42312731392006

10.1016/j.ejca.2006.09.015

17098419

Abi Aad

Pierce

Barmaimon

Farhat

Benjo

Mouhayar

Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge

Crit Rev Oncol Hematol9328352015

10.1016/j.critrevonc.2014.08.004

25217090

Neagoe

Lemieux

Sirois

Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and −2 heterodimer

J Biol Chem280990499122005

10.1074/jbc.M412017200

15637071

Neves

Rios

Jones

Evans

TRJ

Montezano

Touyz

Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury

Cardiovasc Res1159789882019

10.1093/cvr/cvz021

30753341

Hasinoff

Patel

Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib

Cardiovasc Toxicol10182010

10.1007/s12012-009-9056-0

19915982

Semeniuk-Wojtaś

Lubas

Stec

Szczylik

Niemczyk

Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients

Int J Mol Sci1720732016

10.3390/ijms17122073

U.S. Department of Health and Human Services

Common Terminology Criteria For Adverse Events (CTCAE). Version 5.0, 2017

https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5×7.pdf

November272017

Bæk Møller

Budolfsen

Grimm

Krüger

Infanger

Wehland

Magnusson

Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment

Int J Mol Sci2047122019

10.3390/ijms20194712

Tadic

Cuspidi

Belyavskiy

Grassi

Intriguing relationship between antihypertensive therapy and cancer

Pharmacol Res1415015112019

10.1016/j.phrs.2019.01.037

30682424

Pinter

Kwanten

Jain

Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events

Clin Cancer Res24380338122018

10.1158/1078-0432.CCR-18-0236

29610292

Nakaya

Kurata

Yokoi

Iwamoto

Torii

Katashiba

Ogata

Hamada

Kon

Nomura

Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer

Cancer Med5138113872016

10.1002/cam4.701

27109438

Liu

Qin

Wang

Xiong

Bai

Wang

Yang

Sun

Wang

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: A cohort study

J Hematol Oncol101532017

10.1186/s13045-017-0521-0

28870253

Ravaud

Motzer

Pandha

George

Pantuck

Patel

Chang

Escudier

Donskov

Magheli

Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy

N Engl J Med375224622542016

10.1056/NEJMoa1611406

27718781

Escudier

Pluzanska

Koralewski

Ravaud

Bracarda

Szczylik

Chevreau

Filipek

Melichar

Bajetta

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial

Lancet370210321112007

10.1016/S0140-6736(07)61904-7

18156031

Escudier

Eisen

Stadler

Szczylik

Oudard

Siebels

Negrier

Chevreau

Solska

Desai

Sorafenib in advanced clear-cell renal-cell carcinoma

N Engl J Med3561251342007

10.1056/NEJMoa060655

17215530

Rini

Melichar

Ueda

Grünwald

Fishman

Arranz

Bair

Pithavala

Andrews

Pavlov

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial

Lancet Oncol14123312422013

10.1016/S1470-2045(13)70464-9

24140184

Sternberg

Davis

Mardiak

Szczylik

Lee

Wagstaff

Barrios

Salman

Gladkov

Kavina

Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial

J Clin Oncol28106110682010

10.1200/JCO.2009.23.9764

20100962

Akaza

Naito

Ueno

Aoki

Houzawa

Pitman Lowenthal

Lee

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: Efficacy, safety and biomarker analyses in 1689 consecutive patients

Jpn J Clin Oncol455765832015

10.1093/jjco/hyv045

25917359

Rini

Halabi

Rosenberg

Stadler

Vaena

Archer

Atkins

Picus

Czaykowski

Dutcher

Small

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206

J Clin Oncol28213721432010

10.1200/JCO.2009.26.5561

20368558

Ravaud

Sire

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer

Ann Oncol209669672009

10.1093/annonc/mdp201

19403939

Donskov

Michaelson

Puzanov

Davis

Bjarnason

Motzer

Goldstein

Lin

Cohen

Wiltshire

Rini

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Br J Cancer113157115802015

10.1038/bjc.2015.368

26492223

Goldstein

Rosenberg

Figlin

Townsend

McCann

Carpenter

Pandite

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Eur J Cancer53961042016

10.1016/j.ejca.2015.10.006

26702763

Qin

Guo

Xiong

Bai

Sun

Yang

Wang

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial

J Clin Oncol31321932252013

10.1200/JCO.2013.48.8585

23918952

Fuchs

Tomasek

Yong

Dumitru

Passalacqua

Goswami

Safran

Dos Santos

Aprile

Ferry

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial

Lancet38331392014

10.1016/S0140-6736(13)61719-5

24094768

Wilke

Muro

Van Cutsem

Bodoky

Shimada

Hironaka

Sugimoto

Lipatov

Kim

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial

Lancet Oncol15122412352014

10.1016/S1470-2045(14)70420-6

25240821

Qin

Xiong

Bai

Liu

Tong

Liu

Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction

J Clin Oncol34144814542016

10.1200/JCO.2015.63.5995

26884585

Zhou

Chen

Liu

Zhu

Feng

Han

Wang

BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer

J Clin Oncol33219722042015

10.1200/JCO.2014.59.4424

26014294

Sandler

Gray

Perry

Brahmer

Schiller

Dowlati

Lilenbaum

Johnson

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

N Engl J Med355254225502006

10.1056/NEJMoa061884

17167137

Reck

von Pawel

Zatloukal

Ramlau

Gorbounova

Hirsh

Leighl

Mezger

Archer

Moore

Manegold

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

J Clin Oncol27122712342009

10.1200/JCO.2007.14.5466

19188680

Chang

Liu

Shi

Yang

Zhou

Wang

Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in chinese patients with advanced nonsquamous nonsmall-cell lung cancer

J Clin Oncol36120712172018

10.1200/JCO.2017.76.7145

29528793

Saito

Fukuhara

Furuya

Watanabe

Sugawara

Iwasawa

Tsunezuka

Yamaguchi

Okada

Yoshimori

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial

Lancet Oncol206256352019

10.1016/S1470-2045(19)30035-X

30975627

Zhou

Chen

Zhang

Xia

Tong

Zou

Hao

Pan

Zhao

Chen

China national medical products administration approval summary: Anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy

Cancer Commun (Lond)39362019

10.1186/s40880-019-0383-7

31221221

Goodwin

Ding

Seymour

LeMaitre

Arnold

Shepherd

Dediu

Ciuleanu

Fenton

Zukin

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC clinical trials group study BR24

Ann Oncol21222022262010

10.1093/annonc/mdq221

20427348

Koyama

Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab

Cancer Biomark142592652014

10.3233/CBM-140404

24934369

Lin

Luo

Zhou

Shen

Yang

Chen

Xie

Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer

Oncology8114111552017

Sun

Zhang

Zou

Han

Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: A systematic review and meta-analysis

Med Oncol324732015

10.1007/s12032-014-0473-y

25603953

Soria

Mauguen

Reck

Sandler

Saijo

Johnson

Burcoveanu

Fukuoka

Besse

Pignon

meta-analysis of bevacizumab in advanced NSCLC collaborative group

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Ann Oncol2420302013

10.1093/annonc/mds590

23180113

Brahmer

Dahlberg

Gray

Schiller

Perry

Sandler

Johnson

Sex differences in outcome with bevacizumab therapy: Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern cooperative oncology group trial 4599

J Thorac Oncol61031082011

10.1097/JTO.0b013e3181fa8efd

21079521

Leighl

Zatloukal

Mezger

Ramlau

Moore

Reck

Manegold

Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)

J Thorac Oncol5197019762010

10.1097/JTO.0b013e3181f49c22

20978447

Price

Zannino

Wilson

Simes

Cassidy

Van Hazel

Robinson

Broad

Ganju

Ackland

Tebbutt

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C

Ann Oncol23153115362012

10.1016/S0923-7534(20)33130-6

22039086

Aparicio

Bouché

Taieb

Maillard

Kirscher

Etienne

Faroux

Khemissa Akouz

El Hajbi

Locher

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: A randomized phase II trial-PRODIGE 20 study results

Ann Oncol291331382018

10.1093/annonc/mdx808

29045659

Allegra

Yothers

O'Connell

Sharif

Colangelo

Lopa

Petrelli

Goldberg

Atkins

Seay

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

J Clin Oncol27338533902009

10.1200/JCO.2009.21.9220

19414665

Tabernero

Yoshino

Cohn

Obermannova

Bodoky

Garcia-Carbonero

Ciuleanu

Portnoy

Van Cutsem

Grothey

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

Lancet Oncol164995082015

10.1016/S1470-2045(15)70127-0

25877855

Grothey

Cutsem

Sobrero

Siena

Falcone

Ychou

Humblet

Bouché

Mineur

Barone

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial

Lancet3813033122013

10.1016/S0140-6736(12)61900-X

23177514

Bai

Liu

Shen

Wang

Pan

Cao

Zhang

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: A phase Ib study and a randomized double-blind phase II study

J Hematol Oncol10222017

10.1186/s13045-016-0384-9

28103904

Scartozzi

Galizia

Chiorrini

Giampieri

Berardi

Pierantoni

Cascinu

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

Ann Oncol202272302009

10.1093/annonc/mdn637

18842611

Tahover

Uziely

Salah

Temper

Peretz

Hubert

Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

Med Oncol303272013

10.1007/s12032-012-0327-4

23254964

da Silva

de Araujo

Lima

EMEA

Dos Santos

JBR

Silva

MRRD

Almeida

PHRF

de Assis Acurcio

Godman

Kurdi

Cherchiglia

Andrade

EIG

Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: A systematic review and meta-analysis

BioDrugs325856062018

10.1007/s40259-018-0322-1

30499082

Hurwitz

Tebbutt

Kabbinavar

Giantonio

Guan

Mitchell

Waterkamp

Tabernero

Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials

Oncologist18100410122013

10.1634/theoncologist.2013-0107

23881988

Galfrascoli

Piva

Cinquini

Rossi

La Verde

Bramati

Moretti

Manazza

Damia

Torri

Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis

Dig Liver Dis432862942011

10.1016/j.dld.2010.10.010

21146479

Tahover

Hubert

Temper

Salah

Peretz

Hamburger

Uziely

An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: Safety and efficacy with analysis by age group

Target Oncol1055632015

10.1007/s11523-014-0311-3

24599713

Tabernero

Hozak

Yoshino

Cohn

Obermannova

Bodoky

Garcia-Carbonero

Ciuleanu

Portnoy

Prausová

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Ann Oncol6026092018

10.1093/annonc/mdx767

29228087

Obermannová

Van Cutsem

Yoshino

Bodoky

Prausová

Garcia-Carbonero

Ciuleanu

Garcia Alfonso

Portnoy

Cohn

Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

Ann Oncol27208220902016

10.1093/annonc/mdw402

27573561

Cunningham

Lang

Marcuello

Lorusso

Ocvirk

Shin

Jonker

Osborne

Andre

Waterkamp

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial

Lancet Oncol14107710852013

10.1016/S1470-2045(13)70154-2

24028813

Shah

Gressett Ussery

Dowell

Marley

Liticker

Arriaga

Verma

Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

Ann Oncol249609652013

10.1093/annonc/mds593

23175623

Qin

Yau

Pan

Bai

Chi

Wang

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol166196292015

10.1016/S1470-2045(15)70156-7

25981818

Bennouna

Sastre

Arnold

Österlund

Greil

Van Cutsem

von Moos

Viéitez

Bouché

Borg

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial

Lancet Oncol1429372013

10.1016/S1470-2045(12)70477-1

23168366

Hegewisch-Becker

Graeven

Lerchenmüller

Killing

Depenbusch

Steffens

Al-Batran

Lange

Dietrich

Stoehlmacher

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial

Lancet Oncol16135513692015

10.1016/S1470-2045(15)00042-X

26361971

Morse

Sun

Kim

Abada

Mynderse

Finn

The role of angiogenesis in hepatocellular carcinoma

Clin Cancer Res259129202019

10.1158/1078-0432.CCR-18-1254

30274981

Abou-Alfa

Meyer

Cheng

El-Khoueiry

Rimassa

Ryoo

Cicin

Merle

Chen

Park

Cabozantinib in patients with advanced and progressing hepatocellular carcinoma

N Engl J Med37954632018

10.1056/NEJMoa1717002

29972759

Bruix

Qin

Merle

Granito

Huang

Bodoky

Pracht

Yokosuka

Rosmorduc

Breder

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial

Lancet38956662017

10.1016/S0140-6736(16)32453-9

27932229

Zhu

Park

Ryoo

Yen

Poon

Pastorelli

Blanc

Chung

Baron

Pfiffer

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

Lancet Oncol168598702015

10.1016/S1470-2045(15)00050-9

26095784

Zhu

Kang

Yen

Finn

Galle

Llovet

Assenat

Brandi

Pracht

Lim

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol202822962019

10.1016/S1470-2045(18)30937-9

30665869

Akutsu

Sasaki

Takagi

Motoya

Shitani

Igarashi

Hirayama

Wakasugi

Yamamoto

Kaneto

Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

Int J Clin Oncol201051102015

10.1007/s10147-014-0691-5

24744262

Llovet

Ricci

Mazzaferro

Hilgard

Gane

Blanc

de Oliveira

Santoro

Raoul

Forner

Sorafenib in advanced hepatocellular carcinoma

N Engl J Med3593783902008

10.1056/NEJMoa0708857

18650514

Cheng

Kang

Chen

Tsao

Qin

Kim

Luo

Feng

Yang

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial

Lancet Oncol1025342009

10.1016/S1470-2045(08)70285-7

19095497

Meyer

Fox

Ross

James

Sturgess

Stubbs

Stocken

Wall

Watkinson

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial

Lancet Gastroenterol Hepatol25655752017

10.1016/S2468-1253(17)30156-5

28648803

Aalders

Tryfonidis

Senkus

Cardoso

Anti- angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

Cancer Treat Rev53981102017

10.1016/j.ctrv.2016.12.009

28088074

Bear

Tang

Rastogi

Geyer

JrRobidoux

Atkins

Baez-Diaz

Brufsky

Mehta

Fehrenbacher

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

N Engl J Med3663103202012

10.1056/NEJMoa1111097

22276821

Miles

Chan

Dirix

Cortes

Pivot

Tomczak

Delozier

Sohn

Provencher

Puglisi

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

J Clin Oncol28323932472010

10.1200/JCO.2008.21.6457

20498403

Robert

Diéras

Glaspy

Brufsky

Bondarenko

Lipatov

Perez

Yardley

Chan

Zhou

RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

J Clin Oncol29125212602011

10.1200/JCO.2010.28.0982

21383283

Fan

Zhang

Wang

Zhang

Zheng

Shao

Phosphorylated VEGFR2 and hypertension: Potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy

Breast Cancer Res Treat1431411512014

10.1007/s10549-013-2793-6

24292957

Schneider

Wang

Radovich

Sledge

Badve

Thor

Flockhart

Hancock

Davidson

Gralow

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100

J Clin Oncol26467246782008

10.1200/JCO.2008.16.1612

18824714

Cortes

Calvo

Ramírez-Merino

O'Shaughnessy

Brufsky

Robert

Vidal

Muñoz

Perez

Dawood

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis

Ann Oncol23113011372012

10.1093/annonc/mdr432

21976387

Pivot

Schneeweiss

Verma

Thomssen

Passos-Coelho

Benedetti

Ciruelos

von Moos

Chang

Duenne

Miles

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

Eur J Cancer47238723952011

10.1016/j.ejca.2011.06.018

21757334

Rini

Powles

Atkins

Escudier

McDermott

Suarez

Bracarda

Stadler

Donskov

Lee

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial

Lancet393240424152019

10.1016/S0140-6736(19)30723-8

31079938

Yang

Chen

Qin

Wang

Hua

Liu

Clinical observation on hypertenison induced by anti-angiogenic agents for cancer

Chin Clin Oncol196036072014

Yang

Melgarejo

Thijs

Zhang

Boggia

Wei

Hansen

Asayama

Ohkubo

Jeppesen

Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes

JAMA3224094202019

10.1001/jama.2019.9811

31386134

Choueiri

Vaziri

SAJ

Jaeger

Elson

Wood

Bhalla

Small

Weinberg

Sein

Simko

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

J Urol1808608662008

10.1016/j.juro.2008.05.015

18635227

Zhu

Liang

Meng

Chen

Zhang

Guo

Shi

Incidence and risk of sorafenib-induced hypertension: A systematic review and meta-analysis

J Clin Hypertens (Greenwich)161771852014

10.1111/jch.12273

24621095

Frey

Dao

Olvera

Konner

Dickler

Levine

Genetic predisposition to bevacizumab-induced hypertension

Gynecol Oncol1476216252017

10.1016/j.ygyno.2017.09.017

28969913

Scagliotti

Krzakowski

Szczesna

Strausz

Makhson

Reck

Wierzbicki

Albert

Thomas

Miziara

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial

J Clin Oncol30207020782012

10.1200/JCO.2011.39.2993

22564989

Shen

Pan

Dai

Qin

Wang

Yang

Shu

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: Randomized, double-blind, phase III study (AVATAR study)

Gastric Cancer181681762015

10.1007/s10120-014-0351-5

24557418

Schwartzberg

Tauer

Hermann

Makari-Judson

Isaacs

Beck

Kaklamani

Stepanski

Rugo

Wang

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab

Clin Cancer Res19274527542013

10.1158/1078-0432.CCR-12-3177

23444220

Crown

Diéras

Staroslawska

Yardley

Bachelot

Davidson

Wildiers

Fasching

Capitain

Ramos

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

J Clin Oncol31287028782013

10.1200/JCO.2012.43.3391

23857972

Syrigos

Karapanagiotou

Boura

Manegold

Harrington

Bevacizumab-induced hypertension: Pathogenesis and management

BioDrugs251591692011

10.2165/11590180-000000000-00000

21627340

Williams

Mancia

Spiering

Agabiti Rosei

Azizi

Burnier

Clement

Coca

de Simone

Dominiczak

2018 ESC/ESH guidelines for the management of arterial hypertension

Eur Heart J39302131042018

10.1093/eurheartj/ehy339

30165516

Maitland

Bakris

Black

Chen

Durand

Elliott

Ivy

Leier

Lindenfeld

Liu

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

J Natl Cancer Inst1025966042010

10.1093/jnci/djq091

20351338

Figure 1.

Possible mechanism of hypertension induced by antiangiogenic drugs. Monoclonal antibodies block the binding of VEGF to VEGFR, then prevent activation of intracellular signal transduction. Small-molecule TKIs act on the intracellular domain of the VEGFR, where they inhibit the initial phosphorylation step after the ligand-receptor interaction. Blocking the effect of VEGF/VEGFR can inhibit the production of nitric oxide, change the levels of endothelin-1 and reduce the production of capillaries. These effects induce vasoconstriction and inhibit tumor growth and metastasis, but at the same time, vasoconstriction also promotes the increase of blood pressure. In addition, several studies have shown that blocking the VEGF/VEGFR pathway can activate the RAAS, promote water and sodium retention, and raise blood pressure. VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; TKIs, tyrosine kinase inhibitors; RAAS, renin-angiotensin-aldosterone system.

Table I.

Definitions of hypertension grades for adults according to the National Cancer Institute's common terminology criteria for adverse events version 5.0.

Grade	Definition	Treatment
1	Systolic BP 120–139 mm Hg or diastolic BP 80–89 mmHg	NR
2	Systolic BP 140–159 mm Hg or diastolic BP 90–99 mm Hg if previously within normal level; Recurrent or persistent (≥24 h); Symptomatic increase by >20 mm Hg (diastolic) or to >140/90 mm Hg	Monotherapy or change in baseline medical intervention
3	Systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg	NR
4	Life-threatening consequences (for example, malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis)	Urgent intervention
5	Death	–

BP, blood pressure; NR, not reported.

Table II.

Association between antiangiogenic drugs and hypertension in renal cell cancer.

Authors, year	Study type	Phase	Treatment lines	Sample size	Drug	Dose and frequency	Definition of HTN	Incidence of HTN and ≥G3 HTN	Main finding	Refs.
Ravaud et al, 2016	Prospective study	III	First-line after nephrectomy	615	Sunitinib (309) vs. placebo (306)	50 mg, qd, 4 weeks on, 2 weeks off	CTCAE	36.9 and 7.8%	Sunitinib increased the risk of ≥G3 HTN	(16)
Escudier et al, 2007	Prospective study	III	First-line	649	Bevacizumab + IFN-α-2a (327) vs. placebo + IFN-α-2a (322)	10 mg/kg, every two weeks	CTCAE	26 and 3%	Bevacizumab increased the risk of ≥G3 HTN	(17)
Escudier et al, 2007	Prospective study	III	Second-line	903	Sorafenib (451) vs. placebo (452)	400 mg, bid	CTCAE	17 and 4%	Sorafenib increased the risk of ≥G3 HTN	(18)
Rini et al, 2013	Prospective study	II	First-line	213	Axitinib (56) vs. placebo (56)	7 mg and then 10 mg, bid	CTCAE	61 and 18%	Axitinib increased the risk of ≥G3 HTN	(19)
Sternberg et al, 2010	Prospective study	III	NR	435	Pazopanib (290) vs. placebo (145)	NR	CTCAE	40 and 4%	Pazopanib increased the risk of ≥G3 HTN	(20)
Akaza et al, 2015	Prospective study		NR	1′671	Sunitinib	50 mg, once daily	CTCAE	35 and 10%	HTN is potential biomarker for improved survival	(21)
Ravaud and Sire, 2009	Retrospective study		NR	95	Sunitinib Sorafenib Bevacizumab	NR	CTCAE	NR	Significant hypertension predicted clinical benefit	(23)
Rini et al, 2010	Prospective study	III	NR	732	Bevacizumab + IFN-α (369) vs. IFN-α (363)	10 mg/kg every 2 weeks	CTCAE	28 and 11%	Bevacizumab increased the risk of ≥G3 HTN and the development of HTN was an independent predictor of overall survival	(22)
Donskov et al, 2015	Retrospective study		NR	770	Sunitinib	NR	SBP ≥140 mmHg	80%	Hypertension is independent biomarker of sunitinib efficacy	(24)

HTN, hypertension; G3, grade3; CTCAE, common terminology criteria for adverse events; NR, not reported; IFN-α, interferon-α; SBP, systolic blood pressure. qd, once daily; bid, twice daily.

Table III.

Association between anti-angiogenic drugs and hypertension in gastric and gastroesophageal junction cancer.

Authors, year	Study type	Phase	Treatment lines	Sample size	Drug	Dose and frequency	Definition of HTN	Incidence of HTN and ≥G3 HTN	Main finding	Refs.
Li et al, 2013	Prospective study	II	Third or greater the risk of ≥G3 HTN	144	Apatinib (96) vs. placebo (48)	425 mg bid or 850 mg qd	CTCAE	39.13% or 40.43% and 8.51% or 10.87%	Sunitinib increased	(26)
Fuchs et al, 2014	Prospective study	III	Second-line	355	Ramucirumab (238) vs. placebo (117)	8 mg/kg every 2 weeks	CTCAE	16 and 8%	Ramucirumab increased the risk of ≥G3 HTN	(27)
Wilke et al, 2014	Prospective study	III	Second-line	665	Ramucirumab + paclitaxel (330) vs. placebo + paclitaxel (335)	8 mg/kg, day 1,15	CTCAE	24 and 14%	Ramucirumab increased the risk of ≥G3 HTN	(28)
Li et al, 2016	Prospective study	III	Third or greater	267	Apatinib (176) vs. placebo (91)	850 mg qd	CTCAE	35.2 and 4.5%	Apatinib increased the risk of ≥G3 HTN	(29)
Liu et al, 2017	Retrospective cohort study		NR	269	Apatinib	850 mg qd	CTCAE	NR	Presence of HTN was a biomarker of antitumor efficacy	(15)

HTN, hypertension; G3, grade 3; CTCAE, common terminology criteria for adverse events; NR, not reported. qd, once daily; bid, twice daily.

Table IV.

Association between antiangiogenic drugs and hypertension in lung cancer.

Authors, year	Study type	Phase	Treatment lines	Patients	Drug	Dose and frequency	Definition of HTN	Incidence of HTN and ≥G3 HTN	Main finding	Refs.
Zhou et al, 2015	Prospective study	III	First-line	276	Bevacizumab + PC (138) vs. placebo + PC (138)	15 mg/kg, every 21 days	CTCAE	14 and 5%	Bevacizumab increased the risk of HTN	(30)
Lin et al, 2017	Meta-analysis		NR	1,898	Bevacizumab, rh-Endostatin, Vandetanib, Thalidomide, Ziv-aflibercept	NR	CTCAE	NR	Anti-angiogenic drugs increased the risk of ≥G3 HTN	(38)
Sun et al, 2015	Meta-analysis		First and second-line	3,284	Bevacizumab	NR	NR	NR	Bevacizumab increased the risk ≥G3 HTN	(39)
Sandler et al, 2006	Prospective study	III	First-line	878	Bevacizumab + PC (440) vs. PC (427)	15 mg/kg, every 21 days	NR	NR and 7%	Bevacizumab increased the risk of ≥G3 HTN	(31)
Reck et al, 2009	Prospective study	III	First-line	1,043	Bevacizumab + CG (696) vs. placebo+ CG (347)	7.5 or 15 mg/kg, every 21 days	CTCAE	6% or 9%^a	Bevacizumab increased the risk of ≥G3 HTN	(32)
Lu et al, 2018	Prospective study	II	Third-line	91	Fruquintinib (61) vs. placebo (30)	5 mg qd	CTCAE	23 and 8.2%	Fruquintinib increased the risk of ≥G3 HTN	(33)
Soria et al, 2013	Meta-analysis		First-line	2,194	Bevacizumab	NR	NR	NR	Bevacizumab increased the risk of ≥G3 HTN	(40)
Saito et al, 2019	Prospective study	III	NR	228	Bevacizumab + erlotinib (114) vs. erlotinib (114)	15 mg/kg, every 21 days	CTCAE	46 and 23%	Bevacizumab increased the risk of ≥G3 HTN	(34)
Zhou et al, 2019	Prospective study	III	Third-line	437	Anlotinib (294) vs. placebo (143)	12 mg, qd, 2-week on and 1-week off	NR	67.3 and 13.6%	Anlotinib increased the risk of ≥G3 HTN	(35)
Koyama, 2014	Retrospective study		NR	34	Bevacizumab	15 mg/kg, every 21 days	CTCAE	29 and 5.9%	Hypertension may be a prognostic factor for clinical outcome	(37)
Nakaya et al, 2016	Retrospective study		NR	632	Bevacizumab	15 mg/kg, every 21 days	CTCAE	NR	HTN may be a predictive marker for the efficacy	(14)
Goodwin et al, 2010	Prospective study	II	NR	296	Crediranib	30 or 45 mg/day	CTCAE	NR	HTN was favorably prognostic factor for clinical outcome	(36)

Incidence of ≥G3 HTN in group of 7.5 mg/kg vs. group of 15 mg/kg. HTN, hypertension; G3, grade 3; PC, paclitaxel-carboplatin; CTCAE, common terminology criteria for adverse events; CG, cisplatin plus gemcitabine. rh-endostatin, recombinant human endostatin; qd, once daily; bid twice daily.

Table V.

Association between antiangiogenic drugs and hypertension in colorectal cancer.

Authors, year	Study type	Phase	Treatment lines	Sample size	Drug	Dose and frequency	Definition of HTN	Incidence of HTN and ≥G3 HTN	Main finding	Refs.
Price et al, 2012	Prospective study	NR	NR	471	Bevacizumab + CT (315) vs. CT (156)	NR	CTCAE	5.5% or 3.2%^a	Bevacizumab didn't increase the risk of HTN in elderly patients (≥75 years), but increased the risk in young patients (<75 years)	(43)
Aparicio et al, 2018	Prospective study	II	NR	102	Bevacizumab + CT (51) vs. CT (51)	NR	NR	NR and 13.7%	Bevacizumab increased the risk of ≥G3 HTN	(44)
Da Silva et al, 2018	Meta-analysis		NR	10,180	Bevacizumab Cetuximab	NR	CTCAE	NR	Anti-angiogenic drugs increased the risk of ≥G3 HTN	(51)
Hurwitz et al, 2013	Meta-analysis	II–III	First and second line	3,763	Bevacizumab	5, 7.5 or 10 mg/kg	CTCAE	NR	Bevacizumab increased the risk of ≥G3 HTN	(52)
Allegra et al, 2009	Prospective study	III	NR	2,710	Bevacizumab + CT (1354) vs. CT (1356)	5 mg/kg, every two weeks	CTCAE	NR and 12%	Bevacizumab increased the risk of ≥G3 HTN	(45)
Tabernero et al, 2015	Prospective study	III	Second-line	1,072	Ramucirumab + CT (536) vs. placebo + CT (536)	8 mg/kg, every two weeks	CTCAE	26 and 11%	Ramucirumab increased the risk of ≥G3 HTN	(46)
Grothey et al, 2013	Prospective	III	NR	1,052	Regorafenib (505) vs. placebo (255)	160 mg qd	CTCAE	28 and 7%	Regorafenib increased the risk of ≥G3 HTN	(47)
Galfrascoli et al, 2011	Meta-analysis		NR	3,385	Bevacizumab	NR	NR	NR	Bevacizumab increased the risk of ≥G3 HTN	(53)
Xu et al, 2017	Prospective study	Ib-II	NR	113	Fruquintinib (47) vs. placebo (24)	5 mg for 3 weeks on, 1 week off	CTCAE	NR and 29.8%	Fruquintinib increased the risk of ≥G3 HTN	(48)
Scartozzi et al, 2009	Retrospective study		First line	39	Bevacizumab + CT	5 mg/kg every 2 weeks	CTCAE	20%^b	Bevacizumab-induced HTN may represent an interesting prognostic factor for clinical outcome	(49)
Nakaya et al, 2016	Retrospective study		First and second line	315	Bevacizumab	5 mg/kg in first-line and 10 mg/kg in second-line, every 2 weeks	CTCAE	NR	HTN may be a predictive marker for the efficacy	(14)
Tahover et al, 2015	Cohort study		NR	308	Bevacizumab + CT	2.5 mg/kg/week every 2 or 3 weeks	CTCAE	75.3 and 29.2%	HTN is a harbinger of longer overall survival	(54)
Tahover et al, 2013	Retrospective study		NR	181	Bevacizumab + CT	2.5 mg/kg/Week, every 2 or 3 weeks	CTCAE	44.75%^b	HTN may represent a biomarker for clinical benefit	(50)

Incidence of ≥G3 hypertension in elderly patients (≥75 years) vs in young patients (<75 years); bgrades 2–3 hypertension. HTN, hypertension; G3, grade 3; NR, not reported; CT, chemotherapy. qd, once daily.

Table VI.

Association between antiangiogenic drugs and hypertension in hepatocellular carcinoma.

Authors, year	Study type	Phase	Treatment lines	Sample size	Drug	Dose and frequency	Incidence of HTN	Main finding	Refs.
Abou et al, 2018	Prospective study	III	Second or greater	707	Cabozantinib (470) vs. placebo (237)	60 mg qd	29 and 16%	Cabozantinib increased the risk of ≥G3 HTN	(63)
Zhu et al, 2019	Prospective study	III	NR	292	Ramucirumab (197) vs. placebo (95)	8 mg/kg every 2 weeks	25 and 13%	Ramucirumab increased the risk of ≥G3 HTN	(66)
Zhu et al, 2015	Prospective study	III	Second line	562	Ramucirumab (283) vs. placebo (282)	8 mg/kg every 2 weeks	21 and 13%	Ramucirumab as second-line treatment increased the risk of ≥G3 HTN	(65)
Bruix et al, 2017	Prospective study	III	Second line	573	Regorafenib (390) vs. placebo (194)	160 mg qd	23 and 13%	Regorafenib increased the risk of ≥G3 HTN in patients	(64)
Akutsu et al, 2015	Retrospective study		NR	38	Sorafenib	800 or 400 mg/day	58%^a	HTN may be predictor of anticancer efficacy	(67)

Patients who developed grade 2 or higher hypertension within 2 weeks. HTN, hypertension; G3, grade 3; NR, not reported. qd, once daily.

Table VII.

Association between antiangiogenic drugs and hypertension in breast cancer.

Authors, year	Study type	Phase	Treatment line	Sample size	Drug	Dose and frequency	Incidence of HTN (%)	Main finding	Refs.
Bear et al, 2012	Prospective study	NR	NR	1,206	Bevacizumab + CT (595) vs. CT (596)	15 mg/kg, every 3 weeks	NR and 3%	Bevacizumab increased the risk of ≥G3 HTN	(72)
Cortes et al, 2012	Meta-analysis	III	NR	3,792	Bevacizumab	2.5 or 5 mg/kg per week	NR	Bevacizumab increased the risk of ≥G3 HTN	(77)
Miles et al, 2010	Prospective study	III	NR	736	Bevacizumab + CT (495) vs. CT (241)	7.5 or 15 mg/kg every 3 weeks	0.8 and 4.5%^a	Bevacizumab increased the risk of ≥G3 HTN	(73)
Robert et al, 2011	Prospective study	III	NR	1,237	Bevacizumab + CT (824) vs. placebo + CT (423)	15 mg/kg every 3 weeks	NR and 9.83%	Bevacizumab increased the risk of ≥G3 HTN	(74)
Fan et al, 2014	Prospective study		NR	80	Apatinib	750 or 500 mg qd	66.3 and 17.5%	Hypertension was associated with improved clinical outcomes	(75)
Schneider et al, 2008	Retrospective study	III	NR	363	Bevacizumab	NR	NR	Patients with ≥G3 HTN had a superior median overall survival time	(76)

Incidence of ≥G3 hypertension in 7.5 mg/kg group and 15 mg/kg group. HTN, hypertension; G3, grade 3; NR, not reported; CT, chemotherapy. qd, once daily.